Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

ALEJANDRA GONZALEZ-DUARTE

Allopathic & Osteopathic Physicians General Practice

NPI
1922260348
CMS profile
1016035
Location
NEW YORK, NY

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$52,158.61

66 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

By paying entity

PY2024 · entire year · sorted by reported total

Paying entityAmountRecords
AstraZeneca Pharmaceuticals LP $48,609.65 55
Alnylam Pharmaceuticals Inc. $3,548.96 11

Page 2 of 2; records 51–66 of 66 matching records. This page contains 16 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

ALEJANDRA GONZALEZ-DUARTE

NPI 1922260348 · CMS profile ID 1016035

Allopathic & Osteopathic Physicians / General Practice

NEW YORK, NY

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–66 of 66 matching records. This page contains 16 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1922260348?year=2024&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
ALEJANDRA GONZALEZ-DUARTE, NPI 1922260348, CMS profile ID 1016035. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–66 of 66 matching records. This page contains 16 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1922260348?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). ALEJANDRA GONZALEZ-DUARTE, NPI 1922260348, CMS profile ID 1016035. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–66 of 66 matching records. This page contains 16 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1922260348?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
ALEJANDRA GONZALEZ-DUARTE, NPI 1922260348, CMS profile ID 1016035, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–66 of 66 matching records. This page contains 16 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1922260348?year=2024&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

66 matching records · $52,158.61 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 66 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–66 of 66.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
AstraZeneca Pharmaceuticals LP $73.6506/27/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104410515 CMS
AstraZeneca Pharmaceuticals LP $125.0006/27/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105727249 CMS
AstraZeneca Pharmaceuticals LP $93.7806/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104411705 CMS
AstraZeneca Pharmaceuticals LP $3,759.0006/12/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105879546 CMS
Alnylam Pharmaceuticals Inc. $1,081.5005/30/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1125838795 CMS
Alnylam Pharmaceuticals Inc. $637.4705/29/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1125838793 CMS
AstraZeneca Pharmaceuticals LP $664.2705/29/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104767662 CMS
AstraZeneca Pharmaceuticals LP $2,078.6105/29/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104782622 CMS
Alnylam Pharmaceuticals Inc. $125.0005/28/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1125838883 CMS
AstraZeneca Pharmaceuticals LP $850.0005/26/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104524394 CMS
Alnylam Pharmaceuticals Inc. $104.3905/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1125838763 CMS
Alnylam Pharmaceuticals Inc. $599.5804/13/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1125838771 CMS
Alnylam Pharmaceuticals Inc. $193.4304/13/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1125838773 CMS
Alnylam Pharmaceuticals Inc. $55.8304/04/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1125838745 CMS
Alnylam Pharmaceuticals Inc. $55.8304/04/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1125838885 CMS
Alnylam Pharmaceuticals Inc. $514.7003/28/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1125838775 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2021 $4,629.26 8
PY2022 $41,223.35 46
PY2023 $34,140.29 57
PY2024 $52,158.61 66
PY2025 $51,262.35 83

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2021, 2022, 2023, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2021 , PY2022 , PY2023 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $1,233.17 9
PY2025 Principal investigator $188,987.56 98
PY2024 Principal investigator $146,332.01 64

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

107 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Eidos Therapeutics, Inc. $250.00 12/24/2025 Non-covered Recipient Entity
New York University School of Medicine
A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled Study of Acoramidis for Transthyretin Amyloidosis Prevention in the Young (ACT-EARLY Trial) No dispute reported 06/30/2026 1250868731
Principal investigator 1 Eidos Therapeutics, Inc. $350.00 12/24/2025 Non-covered Recipient Entity
New York University School of Medicine
A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled Study of Acoramidis for Transthyretin Amyloidosis Prevention in the Young (ACT-EARLY Trial) No dispute reported 06/30/2026 1250868733
Principal investigator 1 Eidos Therapeutics, Inc. $675.00 12/24/2025 Non-covered Recipient Entity
New York University School of Medicine
A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled Study of Acoramidis for Transthyretin Amyloidosis Prevention in the Young (ACT-EARLY Trial) No dispute reported 06/30/2026 1250868735
Principal investigator 1 Eidos Therapeutics, Inc. $21,216.96 12/24/2025 Non-covered Recipient Entity
New York University School of Medicine
A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled Study of Acoramidis for Transthyretin Amyloidosis Prevention in the Young (ACT-EARLY Trial) No dispute reported 06/30/2026 1250868751
Principal investigator 1 Eidos Therapeutics, Inc. $3,850.00 12/09/2025 Non-covered Recipient Entity
New York University School of Medicine
A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled Study of Acoramidis for Transthyretin Amyloidosis Prevention in the Young (ACT-EARLY Trial) No dispute reported 06/30/2026 1250868741
Principal investigator 1 Eidos Therapeutics, Inc. $12,453.98 11/26/2025 Non-covered Recipient Entity
New York University School of Medicine
A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled Study of Acoramidis for Transthyretin Amyloidosis Prevention in the Young (ACT-EARLY Trial) No dispute reported 06/30/2026 1250868749
Principal investigator 1 Eidos Therapeutics, Inc. $6,563.02 11/07/2025 Non-covered Recipient Entity
New York University School of Medicine
A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled Study of Acoramidis for Transthyretin Amyloidosis Prevention in the Young (ACT-EARLY Trial) No dispute reported 06/30/2026 1250868745
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $135.27 10/29/2025 Non-covered Recipient Entity
NEW YORK UNIVERSITY
Assessment of Hemodynamics, Symptomatology, and Biochemical markers of NPR1 Signaling in Healthy Volunteers and Patients with Postural Orthostatic Tachycardia Syndrome (POTS) and Patients with Neurogenic Orthostatic Hypotension (nOH) No dispute reported 06/30/2026 1184254603
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3.58 10/29/2025 Non-covered Recipient Entity
NEW YORK UNIVERSITY
Assessment of Hemodynamics, Symptomatology, and Biochemical markers of NPR1 Signaling in Healthy Volunteers and Patients with Postural Orthostatic Tachycardia Syndrome (POTS) and Patients with Neurogenic Orthostatic Hypotension (nOH) No dispute reported 06/30/2026 1184254605
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3.58 10/29/2025 Non-covered Recipient Entity
NEW YORK UNIVERSITY
Assessment of Hemodynamics, Symptomatology, and Biochemical markers of NPR1 Signaling in Healthy Volunteers and Patients with Postural Orthostatic Tachycardia Syndrome (POTS) and Patients with Neurogenic Orthostatic Hypotension (nOH) No dispute reported 06/30/2026 1184254607
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3.58 10/29/2025 Non-covered Recipient Entity
NEW YORK UNIVERSITY
Assessment of Hemodynamics, Symptomatology, and Biochemical markers of NPR1 Signaling in Healthy Volunteers and Patients with Postural Orthostatic Tachycardia Syndrome (POTS) and Patients with Neurogenic Orthostatic Hypotension (nOH) No dispute reported 06/30/2026 1184254609
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $89.37 10/29/2025 Non-covered Recipient Entity
NEW YORK UNIVERSITY
Assessment of Hemodynamics, Symptomatology, and Biochemical markers of NPR1 Signaling in Healthy Volunteers and Patients with Postural Orthostatic Tachycardia Syndrome (POTS) and Patients with Neurogenic Orthostatic Hypotension (nOH) No dispute reported 06/30/2026 1184254611
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $89.37 10/29/2025 Non-covered Recipient Entity
NEW YORK UNIVERSITY
Assessment of Hemodynamics, Symptomatology, and Biochemical markers of NPR1 Signaling in Healthy Volunteers and Patients with Postural Orthostatic Tachycardia Syndrome (POTS) and Patients with Neurogenic Orthostatic Hypotension (nOH) No dispute reported 06/30/2026 1184254613
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $142.76 10/29/2025 Non-covered Recipient Entity
NEW YORK UNIVERSITY
Assessment of Hemodynamics, Symptomatology, and Biochemical markers of NPR1 Signaling in Healthy Volunteers and Patients with Postural Orthostatic Tachycardia Syndrome (POTS) and Patients with Neurogenic Orthostatic Hypotension (nOH) No dispute reported 06/30/2026 1184254615
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3.58 10/29/2025 Non-covered Recipient Entity
NEW YORK UNIVERSITY
Assessment of Hemodynamics, Symptomatology, and Biochemical markers of NPR1 Signaling in Healthy Volunteers and Patients with Postural Orthostatic Tachycardia Syndrome (POTS) and Patients with Neurogenic Orthostatic Hypotension (nOH) No dispute reported 06/30/2026 1184254617
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $142.76 10/29/2025 Non-covered Recipient Entity
NEW YORK UNIVERSITY
Assessment of Hemodynamics, Symptomatology, and Biochemical markers of NPR1 Signaling in Healthy Volunteers and Patients with Postural Orthostatic Tachycardia Syndrome (POTS) and Patients with Neurogenic Orthostatic Hypotension (nOH) No dispute reported 06/30/2026 1184254619
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.57 10/29/2025 Non-covered Recipient Entity
NEW YORK UNIVERSITY
Assessment of Hemodynamics, Symptomatology, and Biochemical markers of NPR1 Signaling in Healthy Volunteers and Patients with Postural Orthostatic Tachycardia Syndrome (POTS) and Patients with Neurogenic Orthostatic Hypotension (nOH) No dispute reported 06/30/2026 1184254621
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $89.37 10/29/2025 Non-covered Recipient Entity
NEW YORK UNIVERSITY
Assessment of Hemodynamics, Symptomatology, and Biochemical markers of NPR1 Signaling in Healthy Volunteers and Patients with Postural Orthostatic Tachycardia Syndrome (POTS) and Patients with Neurogenic Orthostatic Hypotension (nOH) No dispute reported 06/30/2026 1184254623
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.57 10/29/2025 Non-covered Recipient Entity
NEW YORK UNIVERSITY
Assessment of Hemodynamics, Symptomatology, and Biochemical markers of NPR1 Signaling in Healthy Volunteers and Patients with Postural Orthostatic Tachycardia Syndrome (POTS) and Patients with Neurogenic Orthostatic Hypotension (nOH) No dispute reported 06/30/2026 1184254625
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $89.37 10/29/2025 Non-covered Recipient Entity
NEW YORK UNIVERSITY
Assessment of Hemodynamics, Symptomatology, and Biochemical markers of NPR1 Signaling in Healthy Volunteers and Patients with Postural Orthostatic Tachycardia Syndrome (POTS) and Patients with Neurogenic Orthostatic Hypotension (nOH) No dispute reported 06/30/2026 1184254627
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $135.27 10/29/2025 Non-covered Recipient Entity
NEW YORK UNIVERSITY
Assessment of Hemodynamics, Symptomatology, and Biochemical markers of NPR1 Signaling in Healthy Volunteers and Patients with Postural Orthostatic Tachycardia Syndrome (POTS) and Patients with Neurogenic Orthostatic Hypotension (nOH) No dispute reported 06/30/2026 1184254629
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $135.27 10/29/2025 Non-covered Recipient Entity
NEW YORK UNIVERSITY
Assessment of Hemodynamics, Symptomatology, and Biochemical markers of NPR1 Signaling in Healthy Volunteers and Patients with Postural Orthostatic Tachycardia Syndrome (POTS) and Patients with Neurogenic Orthostatic Hypotension (nOH) No dispute reported 06/30/2026 1184254631
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $89.37 10/29/2025 Non-covered Recipient Entity
NEW YORK UNIVERSITY
Assessment of Hemodynamics, Symptomatology, and Biochemical markers of NPR1 Signaling in Healthy Volunteers and Patients with Postural Orthostatic Tachycardia Syndrome (POTS) and Patients with Neurogenic Orthostatic Hypotension (nOH) No dispute reported 06/30/2026 1184254633
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $135.27 10/29/2025 Non-covered Recipient Entity
NEW YORK UNIVERSITY
Assessment of Hemodynamics, Symptomatology, and Biochemical markers of NPR1 Signaling in Healthy Volunteers and Patients with Postural Orthostatic Tachycardia Syndrome (POTS) and Patients with Neurogenic Orthostatic Hypotension (nOH) No dispute reported 06/30/2026 1184254635
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $135.27 10/29/2025 Non-covered Recipient Entity
NEW YORK UNIVERSITY
Assessment of Hemodynamics, Symptomatology, and Biochemical markers of NPR1 Signaling in Healthy Volunteers and Patients with Postural Orthostatic Tachycardia Syndrome (POTS) and Patients with Neurogenic Orthostatic Hypotension (nOH) No dispute reported 06/30/2026 1184254637
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $135.27 10/29/2025 Non-covered Recipient Entity
NEW YORK UNIVERSITY
Assessment of Hemodynamics, Symptomatology, and Biochemical markers of NPR1 Signaling in Healthy Volunteers and Patients with Postural Orthostatic Tachycardia Syndrome (POTS) and Patients with Neurogenic Orthostatic Hypotension (nOH) No dispute reported 06/30/2026 1184254639
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $142.76 10/29/2025 Non-covered Recipient Entity
NEW YORK UNIVERSITY
Assessment of Hemodynamics, Symptomatology, and Biochemical markers of NPR1 Signaling in Healthy Volunteers and Patients with Postural Orthostatic Tachycardia Syndrome (POTS) and Patients with Neurogenic Orthostatic Hypotension (nOH) No dispute reported 06/30/2026 1184254641
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3.58 10/29/2025 Non-covered Recipient Entity
NEW YORK UNIVERSITY
Assessment of Hemodynamics, Symptomatology, and Biochemical markers of NPR1 Signaling in Healthy Volunteers and Patients with Postural Orthostatic Tachycardia Syndrome (POTS) and Patients with Neurogenic Orthostatic Hypotension (nOH) No dispute reported 06/30/2026 1184254643
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3.58 10/29/2025 Non-covered Recipient Entity
NEW YORK UNIVERSITY
Assessment of Hemodynamics, Symptomatology, and Biochemical markers of NPR1 Signaling in Healthy Volunteers and Patients with Postural Orthostatic Tachycardia Syndrome (POTS) and Patients with Neurogenic Orthostatic Hypotension (nOH) No dispute reported 06/30/2026 1184254645
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $17.04 10/29/2025 Non-covered Recipient Entity
NEW YORK UNIVERSITY
Assessment of Hemodynamics, Symptomatology, and Biochemical markers of NPR1 Signaling in Healthy Volunteers and Patients with Postural Orthostatic Tachycardia Syndrome (POTS) and Patients with Neurogenic Orthostatic Hypotension (nOH) No dispute reported 06/30/2026 1184254647
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $17.04 10/29/2025 Non-covered Recipient Entity
NEW YORK UNIVERSITY
Assessment of Hemodynamics, Symptomatology, and Biochemical markers of NPR1 Signaling in Healthy Volunteers and Patients with Postural Orthostatic Tachycardia Syndrome (POTS) and Patients with Neurogenic Orthostatic Hypotension (nOH) No dispute reported 06/30/2026 1184254649
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $89.37 10/29/2025 Non-covered Recipient Entity
NEW YORK UNIVERSITY
Assessment of Hemodynamics, Symptomatology, and Biochemical markers of NPR1 Signaling in Healthy Volunteers and Patients with Postural Orthostatic Tachycardia Syndrome (POTS) and Patients with Neurogenic Orthostatic Hypotension (nOH) No dispute reported 06/30/2026 1184254651
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $17.04 10/29/2025 Non-covered Recipient Entity
NEW YORK UNIVERSITY
Assessment of Hemodynamics, Symptomatology, and Biochemical markers of NPR1 Signaling in Healthy Volunteers and Patients with Postural Orthostatic Tachycardia Syndrome (POTS) and Patients with Neurogenic Orthostatic Hypotension (nOH) No dispute reported 06/30/2026 1184254653
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $142.76 10/29/2025 Non-covered Recipient Entity
NEW YORK UNIVERSITY
Assessment of Hemodynamics, Symptomatology, and Biochemical markers of NPR1 Signaling in Healthy Volunteers and Patients with Postural Orthostatic Tachycardia Syndrome (POTS) and Patients with Neurogenic Orthostatic Hypotension (nOH) No dispute reported 06/30/2026 1184254655
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3.58 10/29/2025 Non-covered Recipient Entity
NEW YORK UNIVERSITY
Assessment of Hemodynamics, Symptomatology, and Biochemical markers of NPR1 Signaling in Healthy Volunteers and Patients with Postural Orthostatic Tachycardia Syndrome (POTS) and Patients with Neurogenic Orthostatic Hypotension (nOH) No dispute reported 06/30/2026 1184254657
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.57 10/29/2025 Non-covered Recipient Entity
NEW YORK UNIVERSITY
Assessment of Hemodynamics, Symptomatology, and Biochemical markers of NPR1 Signaling in Healthy Volunteers and Patients with Postural Orthostatic Tachycardia Syndrome (POTS) and Patients with Neurogenic Orthostatic Hypotension (nOH) No dispute reported 06/30/2026 1184254659
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $142.76 10/29/2025 Non-covered Recipient Entity
NEW YORK UNIVERSITY
Assessment of Hemodynamics, Symptomatology, and Biochemical markers of NPR1 Signaling in Healthy Volunteers and Patients with Postural Orthostatic Tachycardia Syndrome (POTS) and Patients with Neurogenic Orthostatic Hypotension (nOH) No dispute reported 06/30/2026 1184254661
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.57 10/29/2025 Non-covered Recipient Entity
NEW YORK UNIVERSITY
Assessment of Hemodynamics, Symptomatology, and Biochemical markers of NPR1 Signaling in Healthy Volunteers and Patients with Postural Orthostatic Tachycardia Syndrome (POTS) and Patients with Neurogenic Orthostatic Hypotension (nOH) No dispute reported 06/30/2026 1184254663
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $17.04 10/29/2025 Non-covered Recipient Entity
NEW YORK UNIVERSITY
Assessment of Hemodynamics, Symptomatology, and Biochemical markers of NPR1 Signaling in Healthy Volunteers and Patients with Postural Orthostatic Tachycardia Syndrome (POTS) and Patients with Neurogenic Orthostatic Hypotension (nOH) No dispute reported 06/30/2026 1184254665
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3.58 10/29/2025 Non-covered Recipient Entity
NEW YORK UNIVERSITY
Assessment of Hemodynamics, Symptomatology, and Biochemical markers of NPR1 Signaling in Healthy Volunteers and Patients with Postural Orthostatic Tachycardia Syndrome (POTS) and Patients with Neurogenic Orthostatic Hypotension (nOH) No dispute reported 06/30/2026 1184254667
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $17.04 10/29/2025 Non-covered Recipient Entity
NEW YORK UNIVERSITY
Assessment of Hemodynamics, Symptomatology, and Biochemical markers of NPR1 Signaling in Healthy Volunteers and Patients with Postural Orthostatic Tachycardia Syndrome (POTS) and Patients with Neurogenic Orthostatic Hypotension (nOH) No dispute reported 06/30/2026 1184254669
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $89.37 10/29/2025 Non-covered Recipient Entity
NEW YORK UNIVERSITY
Assessment of Hemodynamics, Symptomatology, and Biochemical markers of NPR1 Signaling in Healthy Volunteers and Patients with Postural Orthostatic Tachycardia Syndrome (POTS) and Patients with Neurogenic Orthostatic Hypotension (nOH) No dispute reported 06/30/2026 1184254671
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3.58 10/29/2025 Non-covered Recipient Entity
NEW YORK UNIVERSITY
Assessment of Hemodynamics, Symptomatology, and Biochemical markers of NPR1 Signaling in Healthy Volunteers and Patients with Postural Orthostatic Tachycardia Syndrome (POTS) and Patients with Neurogenic Orthostatic Hypotension (nOH) No dispute reported 06/30/2026 1184254673
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3.58 10/29/2025 Non-covered Recipient Entity
NEW YORK UNIVERSITY
Assessment of Hemodynamics, Symptomatology, and Biochemical markers of NPR1 Signaling in Healthy Volunteers and Patients with Postural Orthostatic Tachycardia Syndrome (POTS) and Patients with Neurogenic Orthostatic Hypotension (nOH) No dispute reported 06/30/2026 1184254675
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $89.37 10/29/2025 Non-covered Recipient Entity
NEW YORK UNIVERSITY
Assessment of Hemodynamics, Symptomatology, and Biochemical markers of NPR1 Signaling in Healthy Volunteers and Patients with Postural Orthostatic Tachycardia Syndrome (POTS) and Patients with Neurogenic Orthostatic Hypotension (nOH) No dispute reported 06/30/2026 1184254677
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $89.37 10/29/2025 Non-covered Recipient Entity
NEW YORK UNIVERSITY
Assessment of Hemodynamics, Symptomatology, and Biochemical markers of NPR1 Signaling in Healthy Volunteers and Patients with Postural Orthostatic Tachycardia Syndrome (POTS) and Patients with Neurogenic Orthostatic Hypotension (nOH) No dispute reported 06/30/2026 1184254679
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.57 10/29/2025 Non-covered Recipient Entity
NEW YORK UNIVERSITY
Assessment of Hemodynamics, Symptomatology, and Biochemical markers of NPR1 Signaling in Healthy Volunteers and Patients with Postural Orthostatic Tachycardia Syndrome (POTS) and Patients with Neurogenic Orthostatic Hypotension (nOH) No dispute reported 06/30/2026 1184254681
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $89.37 10/29/2025 Non-covered Recipient Entity
NEW YORK UNIVERSITY
Assessment of Hemodynamics, Symptomatology, and Biochemical markers of NPR1 Signaling in Healthy Volunteers and Patients with Postural Orthostatic Tachycardia Syndrome (POTS) and Patients with Neurogenic Orthostatic Hypotension (nOH) No dispute reported 06/30/2026 1184254683
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $142.76 10/29/2025 Non-covered Recipient Entity
NEW YORK UNIVERSITY
Assessment of Hemodynamics, Symptomatology, and Biochemical markers of NPR1 Signaling in Healthy Volunteers and Patients with Postural Orthostatic Tachycardia Syndrome (POTS) and Patients with Neurogenic Orthostatic Hypotension (nOH) No dispute reported 06/30/2026 1184254685
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3.58 10/29/2025 Non-covered Recipient Entity
NEW YORK UNIVERSITY
Assessment of Hemodynamics, Symptomatology, and Biochemical markers of NPR1 Signaling in Healthy Volunteers and Patients with Postural Orthostatic Tachycardia Syndrome (POTS) and Patients with Neurogenic Orthostatic Hypotension (nOH) No dispute reported 06/30/2026 1184254687
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.57 10/29/2025 Non-covered Recipient Entity
NEW YORK UNIVERSITY
Assessment of Hemodynamics, Symptomatology, and Biochemical markers of NPR1 Signaling in Healthy Volunteers and Patients with Postural Orthostatic Tachycardia Syndrome (POTS) and Patients with Neurogenic Orthostatic Hypotension (nOH) No dispute reported 06/30/2026 1184254689
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $17.04 10/29/2025 Non-covered Recipient Entity
NEW YORK UNIVERSITY
Assessment of Hemodynamics, Symptomatology, and Biochemical markers of NPR1 Signaling in Healthy Volunteers and Patients with Postural Orthostatic Tachycardia Syndrome (POTS) and Patients with Neurogenic Orthostatic Hypotension (nOH) No dispute reported 06/30/2026 1184254691
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3.58 10/29/2025 Non-covered Recipient Entity
NEW YORK UNIVERSITY
Assessment of Hemodynamics, Symptomatology, and Biochemical markers of NPR1 Signaling in Healthy Volunteers and Patients with Postural Orthostatic Tachycardia Syndrome (POTS) and Patients with Neurogenic Orthostatic Hypotension (nOH) No dispute reported 06/30/2026 1184254693
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $89.37 10/29/2025 Non-covered Recipient Entity
NEW YORK UNIVERSITY
Assessment of Hemodynamics, Symptomatology, and Biochemical markers of NPR1 Signaling in Healthy Volunteers and Patients with Postural Orthostatic Tachycardia Syndrome (POTS) and Patients with Neurogenic Orthostatic Hypotension (nOH) No dispute reported 06/30/2026 1184254695
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $89.37 10/29/2025 Non-covered Recipient Entity
NEW YORK UNIVERSITY
Assessment of Hemodynamics, Symptomatology, and Biochemical markers of NPR1 Signaling in Healthy Volunteers and Patients with Postural Orthostatic Tachycardia Syndrome (POTS) and Patients with Neurogenic Orthostatic Hypotension (nOH) No dispute reported 06/30/2026 1184254697
Principal investigator 1 Eidos Therapeutics, Inc. $3,850.00 10/16/2025 Non-covered Recipient Entity
New York University School of Medicine
A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled Study of Acoramidis for Transthyretin Amyloidosis Prevention in the Young (ACT-EARLY Trial) No dispute reported 06/30/2026 1250868739
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,977.97 10/16/2025 Non-covered Recipient Entity
NEW YORK UNIVERSITY SCHOOL OF MEDICINE
A Phase 2 Double-Blind Placebo-Controlled Single-Dose Study of Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of REGN7544, an NPR1 Antagonist Monoclonal Antibody, in Patients With Postural Orthostatic Tachycardia Syndrome No dispute reported 06/30/2026 1184250827
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,620.00 10/03/2025 Non-covered Recipient Entity
NEW YORK UNIVERSITY
Assessment of Hemodynamics, Symptomatology, and Biochemical markers of NPR1 Signaling in Healthy Volunteers and Patients with Postural Orthostatic Tachycardia Syndrome (POTS) and Patients with Neurogenic Orthostatic Hypotension (nOH) No dispute reported 06/30/2026 1184245601
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,500.00 10/03/2025 Non-covered Recipient Entity
NEW YORK UNIVERSITY
Assessment of Hemodynamics, Symptomatology, and Biochemical markers of NPR1 Signaling in Healthy Volunteers and Patients with Postural Orthostatic Tachycardia Syndrome (POTS) and Patients with Neurogenic Orthostatic Hypotension (nOH) No dispute reported 06/30/2026 1184245603
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,565.00 10/03/2025 Non-covered Recipient Entity
NEW YORK UNIVERSITY
Assessment of Hemodynamics, Symptomatology, and Biochemical markers of NPR1 Signaling in Healthy Volunteers and Patients with Postural Orthostatic Tachycardia Syndrome (POTS) and Patients with Neurogenic Orthostatic Hypotension (nOH) No dispute reported 06/30/2026 1184245605
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,500.00 10/03/2025 Non-covered Recipient Entity
NEW YORK UNIVERSITY
Assessment of Hemodynamics, Symptomatology, and Biochemical markers of NPR1 Signaling in Healthy Volunteers and Patients with Postural Orthostatic Tachycardia Syndrome (POTS) and Patients with Neurogenic Orthostatic Hypotension (nOH) No dispute reported 06/30/2026 1184245607
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $500.00 10/03/2025 Non-covered Recipient Entity
NEW YORK UNIVERSITY
Assessment of Hemodynamics, Symptomatology, and Biochemical markers of NPR1 Signaling in Healthy Volunteers and Patients with Postural Orthostatic Tachycardia Syndrome (POTS) and Patients with Neurogenic Orthostatic Hypotension (nOH) No dispute reported 06/30/2026 1184245609
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $20,250.00 10/03/2025 Non-covered Recipient Entity
NEW YORK UNIVERSITY
Assessment of Hemodynamics, Symptomatology, and Biochemical markers of NPR1 Signaling in Healthy Volunteers and Patients with Postural Orthostatic Tachycardia Syndrome (POTS) and Patients with Neurogenic Orthostatic Hypotension (nOH) No dispute reported 06/30/2026 1184245611
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,293.41 09/12/2025 Non-covered Recipient Entity
NEW YORK UNIVERSITY SCHOOL OF MEDICINE
A Phase 2 Double-Blind Placebo-Controlled Single-Dose Study of Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of REGN7544, an NPR1 Antagonist Monoclonal Antibody, in Patients With Postural Orthostatic Tachycardia Syndrome No dispute reported 06/30/2026 1184236678
Principal investigator 1 Eidos Therapeutics, Inc. $2,357.10 08/27/2025 Non-covered Recipient Entity
New York University School of Medicine
A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled Study of Acoramidis for Transthyretin Amyloidosis Prevention in the Young (ACT-EARLY Trial) No dispute reported 06/30/2026 1250868737
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,049.09 08/21/2025 Non-covered Recipient Entity
NEW YORK UNIVERSITY SCHOOL OF MEDICINE
A Phase 2 Double-Blind Placebo-Controlled Single-Dose Study of Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of REGN7544, an NPR1 Antagonist Monoclonal Antibody, in Patients With Postural Orthostatic Tachycardia Syndrome No dispute reported 06/30/2026 1184229791
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,134.70 08/07/2025 Non-covered Recipient Entity
NEW YORK UNIVERSITY SCHOOL OF MEDICINE
A Phase 2 Double-Blind Placebo-Controlled Single-Dose Study of Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of REGN7544, an NPR1 Antagonist Monoclonal Antibody, in Patients With Postural Orthostatic Tachycardia Syndrome No dispute reported 06/30/2026 1184226281
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $95.00 07/31/2025 Non-covered Recipient Entity
NEW YORK UNIVERSITY SCHOOL OF MEDICINE
A Phase 2 Double-Blind Placebo-Controlled Single-Dose Study of Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of REGN7544, an NPR1 Antagonist Monoclonal Antibody, in Patients With Postural Orthostatic Tachycardia Syndrome No dispute reported 06/30/2026 1184222940
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $52.00 07/31/2025 Non-covered Recipient Entity
NEW YORK UNIVERSITY SCHOOL OF MEDICINE
A Phase 2 Double-Blind Placebo-Controlled Single-Dose Study of Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of REGN7544, an NPR1 Antagonist Monoclonal Antibody, in Patients With Postural Orthostatic Tachycardia Syndrome No dispute reported 06/30/2026 1184222942
Principal investigator 1 Eidos Therapeutics, Inc. $9,428.40 07/30/2025 Non-covered Recipient Entity
New York University School of Medicine
A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled Study of Acoramidis for Transthyretin Amyloidosis Prevention in the Young (ACT-EARLY Trial) No dispute reported 06/30/2026 1250868747
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,977.97 07/22/2025 Non-covered Recipient Entity
NEW YORK UNIVERSITY SCHOOL OF MEDICINE
A Phase 2 Double-Blind Placebo-Controlled Single-Dose Study of Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of REGN7544, an NPR1 Antagonist Monoclonal Antibody, in Patients With Postural Orthostatic Tachycardia Syndrome No dispute reported 06/30/2026 1184217891
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,977.97 07/17/2025 Non-covered Recipient Entity
NEW YORK UNIVERSITY SCHOOL OF MEDICINE
A Phase 2 Double-Blind Placebo-Controlled Single-Dose Study of Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of REGN7544, an NPR1 Antagonist Monoclonal Antibody, in Patients With Postural Orthostatic Tachycardia Syndrome No dispute reported 06/30/2026 1184217220
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,815.38 07/10/2025 Non-covered Recipient Entity
NEW YORK UNIVERSITY SCHOOL OF MEDICINE
A Phase 2 Double-Blind Placebo-Controlled Single-Dose Study of Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of REGN7544, an NPR1 Antagonist Monoclonal Antibody, in Patients With Postural Orthostatic Tachycardia Syndrome No dispute reported 06/30/2026 1184214504
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $9,394.32 06/24/2025 Non-covered Recipient Entity
NEW YORK UNIVERSITY SCHOOL OF MEDICINE
A Phase 2 Double-Blind Placebo-Controlled Single-Dose Study of Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of REGN7544, an NPR1 Antagonist Monoclonal Antibody, in Patients With Postural Orthostatic Tachycardia Syndrome No dispute reported 06/30/2026 1184210724
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $6,276.56 06/24/2025 Non-covered Recipient Entity
NEW YORK UNIVERSITY SCHOOL OF MEDICINE
A Phase 2 Double-Blind Placebo-Controlled Single-Dose Study of Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of REGN7544, an NPR1 Antagonist Monoclonal Antibody, in Patients With Postural Orthostatic Tachycardia Syndrome No dispute reported 06/30/2026 1184210726
Principal investigator 1 Eidos Therapeutics, Inc. $4,995.00 06/20/2025 Non-covered Recipient Entity
New York University School of Medicine
A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled Study of Acoramidis for Transthyretin Amyloidosis Prevention in the Young (ACT-EARLY Trial) No dispute reported 06/30/2026 1250868743
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,750.00 05/28/2025 Non-covered Recipient Entity
NEW YORK UNIVERSITY SCHOOL OF MEDICINE
A Phase 2 Double-Blind Placebo-Controlled Single-Dose Study of Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of REGN7544, an NPR1 Antagonist Monoclonal Antibody, in Patients With Postural Orthostatic Tachycardia Syndrome No dispute reported 06/30/2026 1184198985
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $8,037.50 05/28/2025 Non-covered Recipient Entity
NEW YORK UNIVERSITY SCHOOL OF MEDICINE
A Phase 2 Double-Blind Placebo-Controlled Single-Dose Study of Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of REGN7544, an NPR1 Antagonist Monoclonal Antibody, in Patients With Postural Orthostatic Tachycardia Syndrome No dispute reported 06/30/2026 1184198987
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,500.00 05/28/2025 Non-covered Recipient Entity
NEW YORK UNIVERSITY SCHOOL OF MEDICINE
A Phase 2 Double-Blind Placebo-Controlled Single-Dose Study of Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of REGN7544, an NPR1 Antagonist Monoclonal Antibody, in Patients With Postural Orthostatic Tachycardia Syndrome No dispute reported 06/30/2026 1184198989
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $18,002.25 05/28/2025 Non-covered Recipient Entity
NEW YORK UNIVERSITY SCHOOL OF MEDICINE
A Phase 2 Double-Blind Placebo-Controlled Single-Dose Study of Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of REGN7544, an NPR1 Antagonist Monoclonal Antibody, in Patients With Postural Orthostatic Tachycardia Syndrome No dispute reported 06/30/2026 1184198991
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $89.10 04/04/2025 Non-covered Recipient Entity
NEW YORK UNIVERSITY
Assessment of Hemodynamics, Symptomatology, and Biochemical markers of NPR1 Signaling in Healthy Volunteers and Patients with Postural Orthostatic Tachycardia Syndrome (POTS) and Patients with Neurogenic Orthostatic Hypotension (nOH) No dispute reported 06/30/2026 1184181712
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $76.95 04/04/2025 Non-covered Recipient Entity
NEW YORK UNIVERSITY
Assessment of Hemodynamics, Symptomatology, and Biochemical markers of NPR1 Signaling in Healthy Volunteers and Patients with Postural Orthostatic Tachycardia Syndrome (POTS) and Patients with Neurogenic Orthostatic Hypotension (nOH) No dispute reported 06/30/2026 1184181714
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $66.15 04/04/2025 Non-covered Recipient Entity
NEW YORK UNIVERSITY
Assessment of Hemodynamics, Symptomatology, and Biochemical markers of NPR1 Signaling in Healthy Volunteers and Patients with Postural Orthostatic Tachycardia Syndrome (POTS) and Patients with Neurogenic Orthostatic Hypotension (nOH) No dispute reported 06/30/2026 1184181716
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $89.10 04/04/2025 Non-covered Recipient Entity
NEW YORK UNIVERSITY
Assessment of Hemodynamics, Symptomatology, and Biochemical markers of NPR1 Signaling in Healthy Volunteers and Patients with Postural Orthostatic Tachycardia Syndrome (POTS) and Patients with Neurogenic Orthostatic Hypotension (nOH) No dispute reported 06/30/2026 1184181718
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $89.10 04/04/2025 Non-covered Recipient Entity
NEW YORK UNIVERSITY
Assessment of Hemodynamics, Symptomatology, and Biochemical markers of NPR1 Signaling in Healthy Volunteers and Patients with Postural Orthostatic Tachycardia Syndrome (POTS) and Patients with Neurogenic Orthostatic Hypotension (nOH) No dispute reported 06/30/2026 1184181720
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $294.30 04/04/2025 Non-covered Recipient Entity
NEW YORK UNIVERSITY
Assessment of Hemodynamics, Symptomatology, and Biochemical markers of NPR1 Signaling in Healthy Volunteers and Patients with Postural Orthostatic Tachycardia Syndrome (POTS) and Patients with Neurogenic Orthostatic Hypotension (nOH) No dispute reported 06/30/2026 1184181722
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $171.45 04/04/2025 Non-covered Recipient Entity
NEW YORK UNIVERSITY
Assessment of Hemodynamics, Symptomatology, and Biochemical markers of NPR1 Signaling in Healthy Volunteers and Patients with Postural Orthostatic Tachycardia Syndrome (POTS) and Patients with Neurogenic Orthostatic Hypotension (nOH) No dispute reported 06/30/2026 1184181724
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $66.15 04/04/2025 Non-covered Recipient Entity
NEW YORK UNIVERSITY
Assessment of Hemodynamics, Symptomatology, and Biochemical markers of NPR1 Signaling in Healthy Volunteers and Patients with Postural Orthostatic Tachycardia Syndrome (POTS) and Patients with Neurogenic Orthostatic Hypotension (nOH) No dispute reported 06/30/2026 1184181726
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $66.15 04/04/2025 Non-covered Recipient Entity
NEW YORK UNIVERSITY
Assessment of Hemodynamics, Symptomatology, and Biochemical markers of NPR1 Signaling in Healthy Volunteers and Patients with Postural Orthostatic Tachycardia Syndrome (POTS) and Patients with Neurogenic Orthostatic Hypotension (nOH) No dispute reported 06/30/2026 1184181728
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $89.10 04/04/2025 Non-covered Recipient Entity
NEW YORK UNIVERSITY
Assessment of Hemodynamics, Symptomatology, and Biochemical markers of NPR1 Signaling in Healthy Volunteers and Patients with Postural Orthostatic Tachycardia Syndrome (POTS) and Patients with Neurogenic Orthostatic Hypotension (nOH) No dispute reported 06/30/2026 1184181730
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $89.10 04/04/2025 Non-covered Recipient Entity
NEW YORK UNIVERSITY
Assessment of Hemodynamics, Symptomatology, and Biochemical markers of NPR1 Signaling in Healthy Volunteers and Patients with Postural Orthostatic Tachycardia Syndrome (POTS) and Patients with Neurogenic Orthostatic Hypotension (nOH) No dispute reported 06/30/2026 1184181732
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $89.10 04/04/2025 Non-covered Recipient Entity
NEW YORK UNIVERSITY
Assessment of Hemodynamics, Symptomatology, and Biochemical markers of NPR1 Signaling in Healthy Volunteers and Patients with Postural Orthostatic Tachycardia Syndrome (POTS) and Patients with Neurogenic Orthostatic Hypotension (nOH) No dispute reported 06/30/2026 1184181734
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $89.10 04/04/2025 Non-covered Recipient Entity
NEW YORK UNIVERSITY
Assessment of Hemodynamics, Symptomatology, and Biochemical markers of NPR1 Signaling in Healthy Volunteers and Patients with Postural Orthostatic Tachycardia Syndrome (POTS) and Patients with Neurogenic Orthostatic Hypotension (nOH) No dispute reported 06/30/2026 1184181736
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $89.10 04/04/2025 Non-covered Recipient Entity
NEW YORK UNIVERSITY
Assessment of Hemodynamics, Symptomatology, and Biochemical markers of NPR1 Signaling in Healthy Volunteers and Patients with Postural Orthostatic Tachycardia Syndrome (POTS) and Patients with Neurogenic Orthostatic Hypotension (nOH) No dispute reported 06/30/2026 1184181738
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $66.15 04/04/2025 Non-covered Recipient Entity
NEW YORK UNIVERSITY
Assessment of Hemodynamics, Symptomatology, and Biochemical markers of NPR1 Signaling in Healthy Volunteers and Patients with Postural Orthostatic Tachycardia Syndrome (POTS) and Patients with Neurogenic Orthostatic Hypotension (nOH) No dispute reported 06/30/2026 1184181740
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $89.10 04/04/2025 Non-covered Recipient Entity
NEW YORK UNIVERSITY
Assessment of Hemodynamics, Symptomatology, and Biochemical markers of NPR1 Signaling in Healthy Volunteers and Patients with Postural Orthostatic Tachycardia Syndrome (POTS) and Patients with Neurogenic Orthostatic Hypotension (nOH) No dispute reported 06/30/2026 1184181742
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $89.10 04/04/2025 Non-covered Recipient Entity
NEW YORK UNIVERSITY
Assessment of Hemodynamics, Symptomatology, and Biochemical markers of NPR1 Signaling in Healthy Volunteers and Patients with Postural Orthostatic Tachycardia Syndrome (POTS) and Patients with Neurogenic Orthostatic Hypotension (nOH) No dispute reported 06/30/2026 1184181744
Recipient Regeneron Pharmaceuticals, Inc. $16.68 03/20/2025 Covered Recipient Physician A Phase 2 Double-Blind Placebo-Controlled Single-Dose Study of Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of REGN7544, an NPR1 Antagonist Monoclonal Antibody, in Patients With Postural Orthostatic Tachycardia Syndrome No dispute reported 06/30/2026 1184117881
Recipient Regeneron Pharmaceuticals, Inc. $97.10 03/20/2025 Covered Recipient Physician A Phase 2 Double-Blind Placebo-Controlled Single-Dose Study of Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of REGN7544, an NPR1 Antagonist Monoclonal Antibody, in Patients With Postural Orthostatic Tachycardia Syndrome No dispute reported 06/30/2026 1184117883
Recipient Regeneron Pharmaceuticals, Inc. $288.15 03/07/2025 Covered Recipient Physician A Phase 2 Double-Blind Placebo-Controlled Single-Dose Study of Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of REGN7544, an NPR1 Antagonist Monoclonal Antibody, in Patients With Postural Orthostatic Tachycardia Syndrome No dispute reported 06/30/2026 1184117871
Recipient Regeneron Pharmaceuticals, Inc. $66.99 03/07/2025 Covered Recipient Physician A Phase 2 Double-Blind Placebo-Controlled Single-Dose Study of Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of REGN7544, an NPR1 Antagonist Monoclonal Antibody, in Patients With Postural Orthostatic Tachycardia Syndrome No dispute reported 06/30/2026 1184117873
Recipient Regeneron Pharmaceuticals, Inc. $33.71 03/07/2025 Covered Recipient Physician A Phase 2 Double-Blind Placebo-Controlled Single-Dose Study of Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of REGN7544, an NPR1 Antagonist Monoclonal Antibody, in Patients With Postural Orthostatic Tachycardia Syndrome No dispute reported 06/30/2026 1184117875
Recipient Regeneron Pharmaceuticals, Inc. $64.99 03/07/2025 Covered Recipient Physician A Phase 2 Double-Blind Placebo-Controlled Single-Dose Study of Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of REGN7544, an NPR1 Antagonist Monoclonal Antibody, in Patients With Postural Orthostatic Tachycardia Syndrome No dispute reported 06/30/2026 1184117877
Recipient Regeneron Pharmaceuticals, Inc. $32.99 03/07/2025 Covered Recipient Physician A Phase 2 Double-Blind Placebo-Controlled Single-Dose Study of Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of REGN7544, an NPR1 Antagonist Monoclonal Antibody, in Patients With Postural Orthostatic Tachycardia Syndrome No dispute reported 06/30/2026 1184117879
Recipient Regeneron Pharmaceuticals, Inc. $149.99 03/06/2025 Covered Recipient Physician A Phase 2 Double-Blind Placebo-Controlled Single-Dose Study of Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of REGN7544, an NPR1 Antagonist Monoclonal Antibody, in Patients With Postural Orthostatic Tachycardia Syndrome No dispute reported 06/30/2026 1184117869
Recipient Regeneron Pharmaceuticals, Inc. $482.57 02/26/2025 Covered Recipient Physician A Phase 2 Double-Blind Placebo-Controlled Single-Dose Study of Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of REGN7544, an NPR1 Antagonist Monoclonal Antibody, in Patients With Postural Orthostatic Tachycardia Syndrome No dispute reported 06/30/2026 1184117867
Principal investigator 1 Alnylam Pharmaceuticals Inc. $24,301.44 01/09/2025 Covered Recipient Teaching Hospital
Nyu Langone Hospitals
Autonomic dysfunction and peripheral neuropa-thy in patients with cardiac ATTR amyloidosis No dispute reported 06/30/2026 1215509134